跳至主要内容
临床试验/JPRN-UMIN000003658
JPRN-UMIN000003658已完成2 期

Randomized phase II study of gemcitabine monotherapy versus gemcitabine with an EPA-enriched oral supplement in advanced pancreatic cancer (YCOG001) - Randomized phase II study of gemcitabine monotherapy versus gemcitabine with an EPA-enriched oral supplement in advanced pancreatic cancer (YCOG001)

kanagawa cancer center0 个研究点目标入组 66 人开始时间: 2010年5月24日最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
入组人数
66

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1.With moderate or more ascites/pleural effusion 2.Plumonary fibrosis or interstitial pneumonia 3.Cardiac insufficiency or myocardial infarction within six months 4.Active bacterial or fungous infection 5.Uncontrollable diabetes mellitus 6.Psychosis or severe mental disorder 7.Severe drug allergy 8.Simultaneous or metachronous (within 3 years) double cancers, with the exception of intramucosal tumor curable with local therapy 9.Previous chemotherapy or radiotherapy against any other malignancies within 3 years 10.Gemcitabine chemotherapy but with the permission over 6 months after adjuvant chemotherapy 11.Previous therapy against pancreatic cancer 12.With CNS metastasis 13.Pregnant, lactating women or women of childbearing potential 14.Men who want to get partner pregnant 15.Inadequate physical condition, as diagnosed by primary physician

研究者

相似试验

Randomized phase II study of gemcitabine monotherapy... | 临床试验